Douglas Fearon
Born
Douglas Thomas Fearon

(1942-10-16) 16 October 1942[1]
Alma mater
Awards
Scientific career
FieldsImmunology
Websitewww.cshl.edu/Faculty/Douglas-Fearon.html

Douglas Thomas Fearon FRS FRCP FMedSci (born 16 October 1942)[1][2] is an American medical immunologist, who has been since 2003 Sheila Joan Smith Professor of Immunology at the University of Cambridge, a fellow of Trinity College, Cambridge, and a professor at Cold Spring Harbor Laboratory.[3][4][5][6][7]

Awards and honours

Fearon was elected a Fellow of the Royal Society (FRS) in 1999 and is also member of the United States National Academy of Sciences.[3] His nomination for the Royal Society reads:

The research of Douglas T. Fearon has helped establish a unifying principle in immunology; namely, that the two systems of immunity, innate and acquired, are integrated. The former identifies antigens of microbial origin to bias the response of the latter to those antigens. To support this thesis, he has 1) determined how the alternative complement pathway of innate immunity attaches C3 to microbial antigens; 2) demonstrated that the attached C3 causes antigen to be orders of magnitude more potent in eliciting an acquired immune response; and 3) characterised the CR2/CD19 receptor complex of B lymphocytes that mediates the enhanced immunogenicity of C3-bearing antigens, and the counter-regulatory coreceptor, CD22, that suppresses the cellular response to antigen.[8]

References

  1. 1 2 3 "FEARON, Prof. Douglas Thomas". Who's Who. Vol. 2015 (online Oxford University Press ed.). A & C Black. (Subscription or UK public library membership required.)
  2. ↑ "Douglas Fearon". Debretts.
  3. 1 2 Nuzzo, R. (2005). "Biography of Douglas T. Fearon". Proceedings of the National Academy of Sciences. 102 (21): 7415–7417. doi:10.1073/pnas.0502415102. PMC 1140442. PMID 15899974.
  4. ↑ Feig, C; Jones, J. O.; Kraman, M; Wells, R. J.; Deonarine, A; Chan, D. S.; Connell, C. M.; Roberts, E. W.; Zhao, Q; Caballero, O. L.; Teichmann, S. A.; Janowitz, T; Jodrell, D. I.; Tuveson, D. A.; Fearon, D. T. (2013). "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer". Proceedings of the National Academy of Sciences. 110 (50): 20212–7. Bibcode:2013PNAS..11020212F. doi:10.1073/pnas.1320318110. PMC 3864274. PMID 24277834.
  5. ↑ Roberts, E. W.; Deonarine, A; Jones, J. O.; Denton, A. E.; Feig, C; Lyons, S. K.; Espeli, M; Kraman, M; McKenna, B; Wells, R. J.; Zhao, Q; Caballero, O. L.; Larder, R; Coll, A. P.; O'Rahilly, S; Brindle, K. M.; Teichmann, S. A.; Tuveson, D. A.; Fearon, D. T. (2013). "Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia". Journal of Experimental Medicine. 210 (6): 1137–51. doi:10.1084/jem.20122344. PMC 3674708. PMID 23712428.
  6. ↑ Fearon, D. T.; Locksley, R. M. (1996). "The instructive role of innate immunity in the acquired immune response". Science. 272 (5258): 50–3. Bibcode:1996Sci...272...50F. doi:10.1126/science.272.5258.50. PMID 8600536. S2CID 21383755.
  7. ↑ "Douglas Fearon". Cold Spring Harbor Laboratory. Retrieved 30 April 2020.
  8. ↑ "EC/1999/15: Fearon, Douglas Thomas". London: The Royal Society. Archived from the original on 5 April 2015. Retrieved 5 April 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.